We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New Guidelines Aim to Improve AL Amyloidosis Diagnosis

By LabMedica International staff writers
Posted on 02 Feb 2026

Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. More...

  Approximately 3,260 people in the United States are diagnosed with AL amyloidosis each year, and diagnosis typically takes about three years as patients see multiple specialists before identification. The disease remains difficult to recognize because symptoms such as fatigue, dyspnea, and gastrointestinal upset are common to many conditions. The American Society of Hematology (ASH) has now published new clinical practice guidelines that aim to improve and accelerate diagnosis of AL amyloidosis by outlining best practices for evaluating patients with suspected disease.

Published January 27, 2026, in ASH’s peer-reviewed journal Blood Advances, the guidelines were developed through a rigorous evidence-based review and are intended to improve and accelerate diagnostic pathways. Grounded in the latest research, they were created by a multidisciplinary expert panel that included a patient advocate and present 12 distinct recommendations to support the timely diagnosis of AL amyloidosis.

The recommendations call for initial blood and urine testing to assess protein and circulating light chain levels when AL amyloidosis is suspected. For diagnostic confirmation, the guidelines support bone marrow biopsy coupled with fat pad sampling and, in selected cases, advises biopsy of affected organs such as the heart, kidneys, or liver. In addition to the clinical recommendations, the panel conducted a comprehensive literature review to catalog common clinical signs and symptoms of systemic amyloidosis; this review is also published in Blood Advances. 

“These guidelines will be a valuable resource not only for hematologists, but for clinicians across other specialties who care for patients with AL amyloidosis,” said Robert Negrin, MD, ASH President. “Because this is a rare and often underrecognized disorder, these recommendations are particularly important for coordinating care and increasing awareness.”

“For these patients, time is of the essence,” said Vishal Kukreti, MD, chair of the ASH Guidelines on Diagnosis of Light Chain Amyloidosis and a malignant hematologist at Princess Margaret Cancer Centre. “These guidelines will help clinicians across disciplines think of this disease in the right scenarios and provide them the necessary tools to obtain a clear, accurate diagnosis as quickly as possible.”


Related Links:
ASH Clinical Practice Guidelines on Diagnosis and Treatment of Amyloidosis
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.